Stephen Apple Selected Research

Edaravone

1/2022	Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
1/2022	Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
1/2022	Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool.
8/2021	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design.
1/2021	Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study.
1/2021	Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
1/2020	Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
1/2019	Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen Apple Research Topics

Disease

9	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 09/2022 - 01/2019
3	Disease Progression 09/2022 - 01/2021
2	Dyspnea (Shortness of Breath) 09/2022 - 01/2022
1	Neuromuscular Diseases (Neuromuscular Disease) 09/2022
1	Asthenia 09/2022
1	Inflammation (Inflammations) 08/2021

Drug/Important Bio-Agent (IBA)

8	EdaravoneIBA 01/2022 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 08/2021 - 01/2021
1	Pharmaceutical PreparationsIBA 09/2022
1	Biological ProductsIBA 08/2021

Therapy/Procedure

1	Therapeutics 09/2022